NASDAQ:NOVN

Novan Stock Forecast, Price & News

$7.48

-0.55 (-6.85 %)

(As of 07/29/2021 12:00 AM ET)

Add

Compare

Today's Range

$7.48

▼

$8.14

50-Day Range

$0.84

▼

$17.35

52-Week Range

$3.00

▼

$25.90

Volume881,112 shs

Average Volume2.51 million shs

Market Capitalization$140.68 million

P/E RatioN/A

Dividend YieldN/A

Beta-0.03

30 days | 90 days | 365 days | Advanced Chart

Receive NOVN News and Ratings via Email

Sign-up to receive the latest news and ratings for Novan and its competitors with MarketBeat's FREE daily newsletter.

About Novan

Novan, Inc., a clinical development-stage biotechnology company, provides nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. The company was incorporated in 2006 and is based in Durham, North Carolina.

$840,000.00 in Sales Expected for Novan, Inc. (NASDAQ:NOVN) This Quarter
July 27, 2021 | americanbankingnews.com

-$0.53 EPS Expected for Novan, Inc. (NASDAQ:NOVN) This Quarter
July 25, 2021 | americanbankingnews.com

Global Genital Warts Treatment Market to Surpass US$ 2,253.6 Million by 2028, Says Coherent Market Insights (CMI) - Yahoo Finance
July 22, 2021 | finance.yahoo.com

Pritzker Private Capital Appoints Paula Brown Stafford to Pritzker Advisory Board - Business Wire
July 20, 2021 | businesswire.com

Novan, Inc. (NASDAQ:NOVN) Sees Significant Decrease in Short Interest
July 20, 2021 | americanbankingnews.com

Align upgraded at Stephens, Novan surges on Cantor’s bullish call – in today's analyst action - Seeking Alpha
July 9, 2021 | seekingalpha.com

Cantor Fitzgerald Begins Coverage on Novan (NASDAQ:NOVN)
July 9, 2021 | americanbankingnews.com

Novan Announces Inclusion in Russell Microcap® Index - GlobeNewswire
June 24, 2021 | globenewswire.com

Novan Announces Inclusion in Russell Microcap® Index
June 24, 2021 | finance.yahoo.com

Form SC 13G Novan, Inc. Filed by: RA CAPITAL MANAGEMENT, LP - StreetInsider.com
June 22, 2021 | streetinsider.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NOVN
Previous Symbol
CUSIPN/A
CIK1467154
Webwww.novan.com
Phone(919) 485-8080
Employees23
Year FoundedN/A

Sales & Book Value

Annual Sales$4.92 million
Price / Sales28.59
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.21 per share
Price / Book35.62

Profitability

EPS (Most Recent Fiscal Year)($2.60)
Net Income$-29,290,000.00
Net Margins-708.75%
Return on Equity-1,050.18%
Return on Assets-63.06%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares18,807,000
Market Cap$140.68 million
Next Earnings Date8/13/2021 (Estimated)
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

1.38 out of 5 stars

Medical Sector

1059th out of 2,214 stocks

Pharmaceutical Preparations Industry

504th out of 869 stocks

1.5 Analyst's Opinion

Consensus Rating
Novan has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $2.50, Novan has a forecasted downside of 66.6% from its current price of $7.48.
Amount of Analyst Coverage
Novan has only been the subject of 2 research reports in the past 90 days.

3.1 Community Rank

Outperform Votes
Novan has received 232 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Novan has received 140 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Novan has received 62.37% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Novan and other stocks. Vote “Outperform” if you believe NOVN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NOVN will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Novan does not currently pay a dividend.
Dividend Growth
Novan does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Novan insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.70% of the stock of Novan is held by insiders.
Percentage Held by Institutions
80.73% of the stock of Novan is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Novan are expected to grow in the coming year, from ($1.97) to ($1.45) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Novan is -2.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Novan is -2.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Novan has a P/B Ratio of 35.62. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Novan (NASDAQ:NOVN) Frequently Asked Questions

Is Novan a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novan in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Novan stock.
View analyst ratings for Novan or view top-rated stocks.

What stocks does MarketBeat like better than Novan?

Wall Street analysts have given Novan a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Novan wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Novan?

Novan saw a increase in short interest during the month of July. As of July 15th, there was short interest totaling 1,200,000 shares, an increase of 33.2% from the June 30th total of 900,700 shares. Based on an average trading volume of 3,800,000 shares, the short-interest ratio is currently 0.3 days. Approximately 8.3% of the company's shares are short sold.
View Novan's Short Interest.

When is Novan's next earnings date?

Novan is scheduled to release its next quarterly earnings announcement on Friday, August 13th 2021.
View our earnings forecast for Novan.

How were Novan's earnings last quarter?

Novan, Inc. (NASDAQ:NOVN) issued its quarterly earnings data on Tuesday, May, 11th. The company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.05) by $0.01. The business earned $0.82 million during the quarter, compared to analyst estimates of $0.96 million. Novan had a negative trailing twelve-month return on equity of 1,050.18% and a negative net margin of 708.75%.
View Novan's earnings history.

How has Novan's stock been impacted by COVID-19?

Novan's stock was trading at $0.52 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NOVN stock has increased by 1,338.5% and is now trading at $7.48.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for NOVN?

3 brokerages have issued 12 month price targets for Novan's stock. Their forecasts range from $2.00 to $3.00. On average, they anticipate Novan's stock price to reach $2.50 in the next twelve months. This suggests that the stock has a possible downside of 66.6%.
View analysts' price targets for Novan or view top-rated stocks among Wall Street analysts.

Who are Novan's key executives?

Novan's management team includes the following people:

Ms. Paula Brown Stafford, Pres, CEO & Chairwoman (Age 56, Pay $897.86k)
Mr. John M. Gay, CFO & Corp. Sec. (Age 44, Pay $408.03k)
Mr. Andrew J. Novak, VP of Accounting & Bus. Operations and Chief Accounting Officer
Dr. Carri Geer, Sr. VP & CTO
Mr. Cole Ikkala, Director of Investor Relations, Communications & Bus. Devel.
Mr. Stanley Hollenbach BS, J.D., Sr. VP of R&D
Ms. Elizabeth Messersmith, Sr. VP & Chief Devel. Officer

Who are some of Novan's key competitors?

Some companies that are related to Novan include Albireo Pharma (ALBO), Veru (VERU), Marinus Pharmaceuticals (MRNS), Nabriva Therapeutics (NBRV), DiaMedica Therapeutics (DMCAF), Imago BioSciences (IMGO), Evelo Biosciences (EVLO), Pharvaris (PHVS), Spectrum Pharmaceuticals (SPPI), Aldeyra Therapeutics (ALDX), Lexicon Pharmaceuticals (LXRX), AC Immune (ACIU), VistaGen Therapeutics (VTGN), Greenwich LifeSciences (GLSI) and Inventiva (IVA).
View all of NOVN's competitors.

What other stocks do shareholders of Novan own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novan investors own include Bionano Genomics (BNGO), Gran Tierra Energy (GTE), Pennsylvania Real Estate Investment Trust (PEI), ADMA Biologics (ADMA), Cannabics Pharmaceuticals (CNBX), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Aeterna Zentaris (AEZS), CBL & Associates Properties (CBL) and OrganiGram (OGI).

When did Novan IPO?

(NOVN) raised $46 million in an IPO on Wednesday, September 21st 2016. The company issued 3,800,000 shares at a price of $11.00-$13.00 per share. Piper Jaffray acted as the underwriter for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Novan's stock symbol?

Novan trades on the NASDAQ under the ticker symbol "NOVN."

How do I buy shares of Novan?

Shares of NOVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Novan's stock price today?

One share of NOVN stock can currently be purchased for approximately $7.48.

How much money does Novan make?

Novan has a market capitalization of $140.68 million and generates $4.92 million in revenue each year. The company earns $-29,290,000.00 in net income (profit) each year or ($2.60) on an earnings per share basis.

How many employees does Novan have?

Novan employs 23 workers across the globe.

What is Novan's official website?

The official website for Novan is www.novan.com.

Where are Novan's headquarters?

Novan is headquartered at 4105 HOPSON ROAD, MORRISVILLE NC, 27560.

How can I contact Novan?

Novan's mailing address is 4105 HOPSON ROAD, MORRISVILLE NC, 27560. The company can be reached via phone at (919) 485-8080 or via email at [email protected]

This page was last updated on 7/29/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here